BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 5, 2009
View Archived Issues
If This Is a 'V-Shaped'Recovery, Is That 'Victory' or 'Vanquished?'
Read More
New Studies Report Getting iPS Cells from Cord Blood
Read More
Pair Lighting 'Fuzeon' Merger; Trimeris, Korean Firm to Join From
Read More
Clinic Roundup
Read More
Stimulating Recovery Ahead? $5B in Fed Funds to Dole Out
Read More
Financings News
Read More
Other News to Note
Read More
Oncolytics' Phase III Borrows Adaptive Design in SPA Trial
Oncolytics Biotech Inc. reached agreement with the FDA on the design of a Phase III trial of Reolysin in head and neck cancer, marking the first such agreement for an intravenously administered oncolytic virus. (BioWorld Today)
Read More
QLT Sheds Few Eligard Tears, Turns Eye to Punctal-Plug Bid
Read More